Advertisement


Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: KEYNOTE-522 Trial of Pembrolizumab Plus Chemotherapy

ESMO 2019 Congress

Advertisement

Peter Schmid, MD, PhD, of Queen Mary University of London Barts Cancer Institute, discusses pathologic complete response data from a phase III study of pembrolizumab/chemotherapy vs placebo/chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as 6-month adjuvant treatment for early triple-negative breast cancer (Abstract LBA8).



Related Videos

Prostate Cancer

Nicholas D. James, PhD, MBBS, on the STAMPEDE Trial: Long-Term Subgroup Analysis by Metastatic Burden in Hormone-Naive Prostate Cancer

Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses results from a long-term follow-up of a cohort treated with docetaxel in the STAMPEDE randomized trial, confirming that the treatment showed benefit in patients with both high- and low-volume disease (Abstract 844O).

Pancreatic Cancer

Volker Kunzmann, MD, on Advanced Pancreatic Cancer: Findings on nab-Paclitaxel/Gemcitabine and FOLFIRINOX

Volker Kunzmann, MD, of the University of Würzburg/Comprehensive Cancer Center Mainfranken, discusses the final results of a phase II multicenter trial on the conversion rate in locally advanced pancreatic cancer after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (Abstract 671O).

Gynecologic Cancers
Immunotherapy

Nicoletta Colombo, MD, on Lenvatinib/Pembrolizumab for Advanced Endometrial Cancer

Nicoletta Colombo, MD, of Istituto Europeo di Oncologia, discusses the efficacy of lenvatinib/pembrolizumab in metastatic endometrial cancer. The combination showed antitumor activity, regardless of tumor microsatellite instability or DNA mismatch repair status (Abstract 994O).

Hepatobiliary Cancer

Angela Lamarca, MD, PhD, on Liver Metastases From Intrahepatic Cholangiocarcinoma

Angela Lamarca, MD, PhD, of the Christie NHS Foundation Trust, discusses findings from a study that showed new staging criteria should be considered for patients diagnosed with liver metastases in the absence of other extrahepatic tumor spread (Abstract 731P).

Bladder Cancer
Immunotherapy

Thomas Powles, MD, PhD, and Enrique Grande, MD, PhD, on Urothelial Carcinoma: Atezolizumab and Platinum-Based Chemotherapy

Thomas Powles, MD, PhD, of Queen Mary University of London, and Enrique Grande, MD, PhD, of MD Anderson Cancer Center, Madrid, discuss findings of the phase III IMvigor130 trial on the efficacy and safety of atezolizumab as monotherapy or combined with platinum-based chemotherapy vs placebo plus platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (Abstract LBA14).

Advertisement

Advertisement




Advertisement